https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/biomarin-release-results-cln2-trial-being-carried-out-gosh/
Biomarin release results from CLN2 trial being carried out at GOSH
28 Jun 2016, 2:05 p.m.
Biomarin have released positive 48-week results from a clinical trial of cerliponase alfa treatment for CLN2 disease.
CLN2 disease is a form of Batten disease, a fatal neurodegenerative disease. It is the result of mutations in the TPP1/CLN2 gene causing deficient activity of the tripeptidyl peptidase 1 enzyme (TPP1). Cerliponase alfa treatment is a recombinant form of TPP1 and is designed to restore TPP1 enzyme activity.
In this Phase I/II trial, cerliponase alfa treatment was administered directly into the brain ventricles via intracerebroventricular infusions. At one year, the results have shown an 80 per cent reduction in the progression of the disease relating to decline in motor and language functioning, when compared to the natural progression of the disease. Furthermore, treatment was also found to reduce cortical grey matter loss.Biomarin plans to submit marketing applications and is planning to implement an early access programme to enable additional CLN2 patients to have access to this treatment.
The Great Ormond Street Hospital (GOSH) involvement in the trial was led by Novel Therapies Deputy Theme Lead, Professor Paul Gissen.
Celebrating 25 years of saving children’s lives with gene therapy
Marking 25 years since delivering the first ground-breaking gene therapy here at GOSH, having now treated more than 135 children with rare and life-threatening conditions across the world.
A catalyst to unlock the next generation of research leaders
The NIHR GOSH Biomedical Research Centre (BRC) Fellowships are transforming early-career researchers into independent leaders - driving innovation, attracting millions in funding and shaping the future of paediatric science.
Landmark decision to screen for spinal muscular atrophy at birth
Great Ormond Street Hospital (GOSH) is delighted at the announcement that newborn babies in England will be offered screening for spinal muscular atrophy (SMA) through the newborn blood spot, or "heel prick", test programme.
Building the next generation of paediatric research leaders
From early career clinicians to emerging scientists, the NIHR GOSH Biomedical Research Centre (BRC)’s Academic Training Weekend is shaping the future of paediatric research - bringing together talent, expertise and ambition from across the UK.